普萘洛尔治疗婴幼儿血管瘤专家共识

血管瘤是儿童最常见的良性血管肿瘤,在l岁以内儿童中的发病率约为10％.对于生长迅速及出现并发症的患者,需要积极治疗.目前的治疗手段包括药物治疗、激光治疗和手术治疗,首选药物治疗.自2008年偶然发现对血管瘤有效以来,普萘洛尔已经成为治疗血管瘤的一线药物,但其剂量、用药方案、疗程、不良作用监测等均无统一标准.2012年12月,来自12家单位、5个不同专业的28名专家汇集芝加哥,根据现有文献资料,就普萘洛尔治疗血管瘤的相关问题达成了共识.

Introduction to a consensus conference on the use of propranolol for infantile hemangioma

Infantile hemangioma （IH） is the most common benign vascular tumor of childhood, with an incidence of about 10% at the end of the first year. The majority of infantile hemangiomas can be closely observed, while infants with rapidly growing and complicated IH should be treated agressively. The documented treatment options for IH included drug therapy, laser therapy and surgical excision, with drug therapy as the treatment of choice. Since the serendipitous discovery of its efficacy in IH in 2008, propranolol has become the first-line treatment for these benign tumours. However, dose initiation, protocol, adverse events monitoring were extremely variable among different institutions. A muhidiseiplinary, multiinstitutional expert panel met in December 2012 in Chicago to develop a standardized, consensus derived set of best practices for the use of propranolol in infants with IH. As more information accumulates, this provisional set of best practices will be updated.